Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list
Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic from its shortage list, a move that will sharply curtail the compounders' ability to sell cheaper versions of the drugs.
Wegovy and Ozempic, both known chemically as semaglutide, were in shortage in the U.S. for much of last year. More on semaglutide compounds:Shortage of popular drugs Wegovy and Ozempic is ...
The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback